Pharmacokinetics of Haloperidol Decanoate

Depot Antipsychotic Drugs

Davis, J. M., Metalon, L., Watanabe, M. D., & Blake, L. M. (1994) · Drugs · doi:10.2165/00003495-199447050-00004 · Cited by 295 · see citing works

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works

Pharmacokinetics of Haloperidol

Froemming, J. S., Lam, Y. W. F., Jann, M. W., & Davis, C. M. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198917060-00004 · Cited by 292 · see citing works

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview

Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205 · see citing works

Lamina-Specific Deficits in Parvalbumin-Immunoreactive Varicosities in the Prefrontal Cortex of Subjects With Schizophrenia: Evidence for Fewer Projections From the Thalamus

Lewis, D. A., Cruz, D. A., Melchitzky, D. S., & Pierri, J. N. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1411 · Cited by 190 · see citing works

Long Term Depot Antipsychotics

Barnes, T. R. E., & Curson, D. A. (1994) · Drug Safety · doi:10.2165/00002018-199410060-00005 · Cited by 130 · see citing works

Clinical Pharmacokinetics of the Depot Antipsychotics

Jann, M. W., Ereshefsky, L., & Saklad, S. R. (1985) · Clinical Pharmacokinetics · doi:10.2165/00003088-198510040-00003 · Cited by 125 · see citing works

Haloperidol Decanoate: A Preliminary Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Psychosis

Beresford, R., & Ward, A. (1987) · Drugs · doi:10.2165/00003495-198733010-00002 · Cited by 90 · see citing works

Release and absorption rate aspects of intramuscularly injected pharmaceuticals

Zuidema, J., Pieters, F. A. J. M., & Duchateau, G. S. M. J. E. (1988) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(88)90209-8 · Cited by 72 · see citing works

Plasma Levels of Fluphenazine in Patients Receiving Fluphenazine Decanoate Relationship to Clinical Response

Marder, S. R., Midha, K. K., Putten, T. V., Aravagiri, M., Hawes, E. M., Hubbard, J. W., McKay, G., & Mintz, J. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.5.658 · Cited by 56 · see citing works

The Bioavailability and Pharmacokinetics of Oral and Depot Intramuscular Haloperidol in Schizophrenic Patients

Nayak, R. K., Doose, D. R., & Nair, N. P. V. (1987) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1987.tb02175.x · Cited by 55 · see citing works

Antipsychotic Drugs

Balant-Gorgia, A. E., & Balant, L. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198713020-00001 · Cited by 53 · see citing works

Delayed Normalization of Central D2 Dopamine Receptor Availability After Discontinuation of Haloperidol Decanoate

Nyberg, S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220079011 · Cited by 51 · see citing works

Depot Neuroleptic Therapy: Clinical Considerations

Gary, J. R., & Martha, E. A. (1995) · The Canadian Journal of Psychiatry · doi:10.1177/070674379504003s02 · Cited by 49 · see citing works

Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs.

Schoretsanitis, G., Baumann, P., Conca, A., Dietmaier, O., Giupponi, G., Gründer, G., Hahn, M., Hart, X., Havemann-Reinecke, U., Hefner, G., et al. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000830 · Cited by 28 · see citing works

Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications

Marder, S. R., Hubbard, J. W., Putten, T. V., & Midha, K. K. (1989) · Psychopharmacology · doi:10.1007/bf00441937 · Cited by 47 · see citing works

Depot haloperidol decanoate for schizophrenia

Quraishi, S. N., David, A. S., Brasil, M. A. A., & Alheira, F. V. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001361 · Cited by 43 · see citing works

Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients

Nyberg, S., Farde, L., & Halldin, C. (1996) · Psychiatry Research Neuroimaging · doi:10.1016/0925-4927(96)02921-6 · Cited by 40 · see citing works

Pharmacokinetics and Therapeutic Efficacy of Haloperidol Decanoate after Loading Dose Administration

Cuyper, H. D., Bollen, J., van Praag, H. M., & Verstraeten, D. (1986) · The British Journal of Psychiatry · doi:10.1192/bjp.148.5.560 · Cited by 30 · see citing works

Haloperidol decanoate and flupenthixol decanoate in schizophrenia

Eberhard, G., & Hellbom, E. (1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb06242.x · Cited by 24 · see citing works

A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients

Dencker, S. J., Giös, I., Mårtensson, E., Nordén, T., Nyberg, G., Persson, R., Román, G. C., Stockman, O., & Svärd, K.-O. (1994) · Psychopharmacology · doi:10.1007/bf02245440 · Cited by 22 · see citing works

Chemotherapy With Neuroleptics

Knudsen, P. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb08540.x · Cited by 20 · see citing works

Haloperidol Decanoate v. Fluphenazine Decanoate as Maintenance Therapy in Chronic Schizophrenic In-patients

McKane, J. P., Robinson, A. D. T., Wiles, D. H., McCreadie, R. G., & Stirling, G. S. (1987) · The British Journal of Psychiatry · doi:10.1192/bjp.151.3.333 · Cited by 19 · see citing works

Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia

Wiles, D. H., McCreadie, R. G., & Whitehead, A. (1990) · Psychopharmacology · doi:10.1007/bf02244140 · Cited by 19 · see citing works

A Loading-Dose Strategy for Converting From Oral to Depot Haloperidol

Ereshefsky, L., Toney, G., Saklad, S. R., Anderson, C., & Seidel, D. R. (1993) · Psychiatric Services · doi:10.1176/ps.44.12.1155 · Cited by 19 · see citing works

Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levels

Altamura, C. A., Colacurcio, F., Kauri, M. C., Moro, A. R., & Novellis, F. D. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90061-k · Cited by 16 · see citing works

Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal

Chang, W., Lin, S., Juang, D. J., Chen, L.-C., Yang, C.-H., Hu, W.-H., Chien, C.-P., Lam, Y.-K., & Jann, M. W. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90007-6 · Cited by 14 · see citing works

Haloperidol Decanoate: A Depot Antipsychotic

Hemstrom, C. A., Evans, R. L., & Lobeck, F. G. (1988) · Annals of Pharmacotherapy · doi:10.1177/106002808802200402 · Cited by 14 · see citing works

High-performance liquid chromatographic analysis of haloperidol and hydroxyhaloperidol in plasma after solid-phase extraction

Cahard, C., Rop, P. P., Conquy, T., et al. (1990) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83769-x · Cited by 13 · see citing works

19F‐magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate

SASSA, T., Suhara, T., Ikehira, H., et al. (2002) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2002.01068.x · Cited by 12 · see citing works

Comparative bioavailability study of two haloperidol decanoate containing products

van Weringh, G., Komen, B. J., Thieme, R. E., van der Hoeven, R. T. M., & Vos, T. (1994) · Pharmacy World & Science · doi:10.1007/bf02178564 · Cited by 8 · see citing works

Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate

Jann, M. W., Weui, F.-C., Lin, H.-N., Piao-Chien, C., & Chang, W. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00293-6 · Cited by 7 · see citing works

Depot antipsychotics revisited

Taylor, D. M. (1999) · Psychiatric Bulletin · doi:10.1192/pb.23.9.551 · Cited by 7 · see citing works

Plasma Level Monitoring for Maintenance Neuroleptic Therapy

Marder, S. R., Putten, T. V., & Aravagiri, M. (1989) · Springer eBooks · doi:10.1007/978-3-642-74430-3_31 · Cited by 7 · see citing works

Do enzyme inducers modify haloperidol decanoate rate of release?

Pupeschi, G., AGENET, C., Levron, J., et al. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90096-5 · Cited by 5 · see citing works

Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics

Weh-Ho, C., Shih-Ku, L., Dong-juiing, J., et al. (1993) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90035-q · Cited by 3 · see citing works

Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration

Chang, W., Juang, D. J., Lin, S., Huang, J., Lam, Y. F., Jann, M. W., & Chien, C. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100108 · Cited by 2 · see citing works

Haloperidol in the Treatment of Psychosis

Laux, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_127 · Cited by 1 · see citing works

Pharmacokinetic aspects of the treatment with long-acting injectable antipsychotics and specific features of the first generation preparations

Hýža, M., & Skřont, T. (2025) · Psychiatrie pro praxi · doi:10.36290/psy.2025.013 · Cited by 1 · see citing works

Butyrophenone und strukturanaloge Verbindungen

Heininger, K., Klimke, A., Gäebel, W., Bandelow, B., Rüther, E., Klieser, E., & Lemmer, W. (1998) · Springer eBooks · doi:10.1007/978-3-7091-6458-7_7 · Cited by 1 · see citing works

Psychotropic Agents

Perry, P. J. (2002) · CRC Press eBooks · doi:10.1201/9781420010084.ch9 · Cited by 1 · see citing works

Pharmacokinetic data on antiparkinson and related agents

Jack, D. B. (1992) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-22495-1_15

Haloperidol in the Treatment of Psychosis

Laux, G. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_127-1

Pharmakologie

Heininger, K., Gäebel, W., Klimke, A., & Fritze, J. (1998) · Springer eBooks · doi:10.1007/978-3-7091-6458-7_3

Switching Haloperidol from Oral to Im Depot Formulation

Perry, P. J., & ALEXANDER, B. K. (1991) · DICP · doi:10.1177/106002809102501121

Allgemeine Grundlagen der Pharmakokinetik und Pharmakodynamik

Buclin, T., & Baumann, P. (1992) · Springer eBooks · doi:10.1007/978-3-7091-6674-1_11

Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio.

Lam, Y.-W. F., Chang, W. H., Jann, M. W., et al. (1992) · PubMed · Cited by 8 · see citing works

Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal

Chang, W., Lin, S., Juang, D. J., Chen, L.-C., Yang, C.-H., Hu, W.-H., Chien, C.-P., Lam, Y.-K., & Jann, M. W. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90007-6 · Cited by 14 · see citing works

Haloperidol plasma concentrations in Taiwanese psychiatric patients.

Lane, H., Lin, H., Hwu, H., et al. (1995) · PubMed · Cited by 13 · see citing works

Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics

Weh-Ho, C., Shih-Ku, L., Dong-juiing, J., et al. (1993) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90035-q · Cited by 3 · see citing works

Reduced haloperidol: Effects on striatal dopamine metabolism and conversion to haloperidol in the rat

Korpi, E. R., & Wyatt, R. J. (1984) · Psychopharmacology · doi:10.1007/bf00427418 · Cited by 62 · see citing works